PROTOKOLwiki
COMPOUNDS / NOOTROPIC / EMOXYPINE
NOOTROPIC

EMOXYPINE

LOW RISK
BEST FOR:Neuroprotection●●●●●●○○○○6/10
EMOXYPINE · MEXIDOL · MEXICOR · EMOXYPINE SUCCINATE · 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE · EMHP · ETHYLMETHYLHYDROXYPYRIDINE · ARMADIN · ARMADIN LONG · EMIDONOL · MEXIDOL SUCCINATE
NootropicAntioxidantSoviet / RussianNeuroprotectiveCardioprotectiveAntihypoxant

Synthetic B6-derived antioxidant and antihypoxant used in Russia for neuroprotection, cardiology, and cognitive support.

ROUTE / DOSAGE
LOW100mg
STANDARD200-400mg
HIGH600mg+
Note: Typically dosed 1-3x daily; available as tablets or capsules
CYCLE
Daily use acceptable courses of 2-6 weeks common in clinical practice
BIOAVAILABILITY
~50% oral near-complete IM/IV
ACTIVE DURATION
4-6h (subjective)
STORAGE
Room temperature dry away from light injectable forms stored per manufacturer guidelines
HALF-LIFE
2-4 hours (plasma)
DURATION BREAKDOWN
Total4-6 hours
Onset30-60 min
Come up30-60 min
Peak1-2 hours
Offset2-3 hours
After effects2-4 hours
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
7 documented
Antioxidant free-radical scavenging
Antihypoxic and anti-ischemic effects
Neuroprotective and cognition-supporting
Cardioprotective and coronarolytic
Platelet aggregation inhibition
Iron chelation
Anti-inflammatory (reduces IL-1β, TNF-α)
§ 02 — RISKS
Potential unintended meldonium doping positive in athletes via contaminated milk
Limited Western clinical trial data; most evidence from Russian-language studies
Allergic reactions possible with injectable forms
May interact with antiplatelet/anticoagulant medications
Long-term safety data outside Russian clinical practice is limited
§ 03 — INTERACTIONS
Interaction data not yet available for this compound.
§ 04 — SCIENCE

Emoxypine is a registered pharmaceutical in Russia and Ukraine under multiple trade names (Mexidol, Mexicor, Armadin) but lacks approval in Western markets. Preclinical and clinical studies from Russia report antioxidant, antihypoxic, neuroprotective, and cardioprotective effects, with evidence of improved outcomes in ischemic stroke, heart failure, and cognitive disorders. A 2022 review highlighted iron-chelating properties and potential in neurodegenerative disease management. A 2024 zebrafish study demonstrated reduction of neuroinflammation markers (IL-1β, TNF-α, NLRP3) and improved behavioral outcomes. However, most evidence comes from Russian-language studies and animal models; large-scale randomized controlled trials in Western populations are lacking. A 2024 doping analysis paper noted that emoxypine and meldonium can co-appear in urine from contaminated milk, raising concerns about unintended doping positives.

§ 06 — SOURCES
[1]
Promising effects of emoxypine and its succinate derivative in the management of various diseases
pubmed.ncbi.nlm.nih.gov ↗
[2]
Emoxypine succinate modulates behavioral and molecular responses in zebrafish model of iron overload-induced neuroinflammation
pubmed.ncbi.nlm.nih.gov ↗
[3]
Pharmaceutical salts of emoxypine with dicarboxylic acids
pubmed.ncbi.nlm.nih.gov ↗
[4]
Emoxypine as a Potential Marker for Identifying Possible Cases of Unintended Meldonium Doping in Sports
pubmed.ncbi.nlm.nih.gov ↗
[5]
Mexidol, Cytoflavin, and succinic acid derivatives as antihypoxic, anti-ischemic metabolic modulators, and ergogenic aids in athletes
pubmed.ncbi.nlm.nih.gov ↗
[6]
Effect of magnesium, acetylsalicylic acid and emoxypine on aggregation of platelets
pubmed.ncbi.nlm.nih.gov ↗
[7]
The effect of the synthetic antioxidant emoxypine on the tonus of the coronary vessels
pubmed.ncbi.nlm.nih.gov ↗
[8]
Efficacy of emoxypine in combined therapy for elderly patients with postinfarct cardiosclerosis and heart failure
pubmed.ncbi.nlm.nih.gov ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT